MiNK Therapeutics
Tracked across 7 events · 127 articles · First seen Oct 06, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.
Apr 01, 2026 · 6 articles
Business
Impact: MiNK Therapeutics is being acquired by Neurocrine Biosciences for $2.9 billion, representing a significant premium for its shareholders. Its product, VYKAT XR, is a key asset in this transaction.
Apr 06, 2026 · 6 articles
Business
Multiple investor-rights law firms, including The Schall Law Firm, Faruqi & Faruqi, Bronstein, Gewirtz & Grossman, LLC, The Law Offices of Frank R. Cruz, Rosen Law Firm, and Pomerantz LLP, have filed class action lawsuits…
Impact: MiNK Therapeutics is the primary defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about the safety and commercial viability of its drug candidate, DCCR. The company's stock price has significantly declined following reports of safety concerns, a patient death, and disruptions in DCCR's launch.
Apr 01, 2026 · 83 articles
Tech
MiNK Therapeutics announced its placement in editorials published by BioMedWire, highlighting its novel approach to drug and alcohol intoxication detection. The company is leveraging artificial intelligence and voice analysis to predict impairment from short speech…
Impact: MiNK Therapeutics is developing an AI and voice analysis platform for real-time drug and alcohol intoxication detection, addressing a critical gap in existing methods and potentially transforming various industries.
May 12, 2026 · 8 articles
Tech
Impact: MiNK Therapeutics, a subsidiary of Bayer, is exploring approaches related to regulatory T cells, contributing to the development of new treatments.
Oct 06, 2025 · 6 articles
100
The Schall Law Firm filed class action lawsuit MiNK TherapeuticsSoleno Therapeutics DCCR...
95
Kahn Swick & Foti notifies investors of lawsuit MiNK TherapeuticsSoleno Therapeutics DCCR...
95
Faruqi & Faruqi investigating claims MiNK TherapeuticsSoleno Therapeutics DCCR...
90
MiNK Therapeutics reported financial resultsSoleno Therapeutics DCCR...
90
MiNK Therapeutics filed Form 8-K United States — United States Securities and Exchange CommissionSoleno Therapeutics DCCR...
90
MiNK Therapeutics advanced novel approachMindBio AI Intoxication Detection
90
Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit MiNK TherapeuticsSoleno Therapeutics DCCR...
90
Pomerantz LLP filed lawsuit MiNK TherapeuticsSoleno Therapeutics DCCR...
86
MiNK Therapeutics made misleading statementsSoleno Therapeutics DCCR...
85
MiNK Therapeutics reported financial resultsSoleno Therapeutics DCCR...
82
Scorpion Capital issued report MiNK TherapeuticsSoleno Therapeutics DCCR...
75
Rosen Law Firm filed class action lawsuit MiNK TherapeuticsSoleno Therapeutics DCCR...
NEWSDESK
Track MiNK Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard